Beckman's automated PSA (prostate specific antigen) tests receive FDA green light
This article was originally published in Clinica
Beckman Coulter has received a premarket approval from the US FDA for its automated Hybritech total PSA and Hybritech free PSA blood tests, designed for the diagnosis of prostate cancer.
You may also be interested in...
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.
The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.